FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma

Skeletal Radiology

Volumn 32, Issue 3, 2003, Pages 139-142

  Vernon, Cheryl B ^a,b   Eary, Janet F ^a   Rubin, Brian P ^c   Conrad, Ernest U ^c   Schuetze, Scott ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

FDG; Neoadjuvant therapy; Neoadjuvant therapy response; PET; Sarcoma; SUV

Indexed keywords

DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CASE REPORT; DIAGNOSTIC IMAGING; DRUG RESPONSE; DRUG UPTAKE; HISTOPATHOLOGY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SOFT TISSUE SARCOMA; TISSUE METABOLISM; TREATMENT PLANNING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; MIDDLE AGED; PATHOLOGY; SARCOMA; SCINTISCANNING; SOFT TISSUE TUMOR; THIGH;

CHEMOTHERAPY, ADJUVANT; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; SARCOMA; SOFT TISSUE NEOPLASMS; THIGH; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0038725463     PISSN: 03642348     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00256-002-0607-8     Document Type: Article

References (11)

1. Franzius C, Sciuk J, Brinkschmidt C, Jurgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000; 25:874-881.
2. Schulte M, Brecht-Krauss D, Werner M, Hartwig E, Sarkar MR, Keppler P, Kotzerke J, Guhlmann A, Delling G, Reske SN. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999; 40:1637-1643.
3. Eary JF, Conrad EU. Positron emission tomography in grading soft tissue sarcomas. Semin Musculoskeletal Radiol 1999; 3:135-138.
4. Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med 1998; 39:250-254.
5. Eary JF, Conrad EU, Bruckner JD, Folpe A, Hunt KJ, Mankoff DM, Howleet AT. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pre-treatment grading of sarcoma. Clin Cancer Res 1998; 4:1215-1220.
6. Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, Burger C, Heichel T, Willeke F, Mechtersheimer G, Lehnert T. Dynamic PET18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001; 42:713-720.
7. Eary JF, O'Sullivan F, Pawian Y, Chandhury KR, Vernon CB, Bruckner JD, Conrad EU. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med 2002; 29:1150-1154.
8. Folpe AL, Lyles RH, Sprouse JT, Conrad EU III, Eary JF. (F-18)fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000; 6:1279-1287.
9. Eilber FC, Rosen G, Eckardt J, Forscher C, Nelson SD, Selch M, Dorey F, Eilber FR. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001; 19:3203-3209.
10. O'Sullivan F, Roy S, Eary JF. A measure of tissue heterogeneity with application to 3-D PET sarcoma data. J Am Stat Assoc (in press).
11. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU, Eary JF. FDG positron emission tomography predicts histopathologic response and survival in patients with resectable, localized soft tissue sarcoma. J Clin Oncol (in press).